Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
MetLife, Inc. director Diana McKenzie acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share under the company’s non‑management director compensation program. The filing states that a portion of non‑management director retainer fees are paid in common stock and that Ms. McKenzie elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non‑Management Directors. After this transaction she beneficially owns 22,757 shares, reported as direct ownership. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The disclosure is limited to the director grant and deferral; no additional financial results, guidance, or other transactions are included in this filing.
MetLife, Inc. (MET) non-management director Christian Stephane Mumenthaler reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction he beneficially owned 1,458 shares. The filing states these shares were part of director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The report reflects a routine compensation-related equity grant and deferral by a board member.
The Form 4 shows that Mark A. Weinberger, a non‑management director of MetLife, Inc. (MET), received 534 shares of MetLife common stock as part of the company's director compensation plan on 10/01/2025. After this award, his beneficial ownership totaled 17,441 shares. The filing states these shares were issued under MetLife's practice of paying a portion of non‑management director retainer fees in common stock.
Robert Glenn Hubbard, a non-management director of MetLife, Inc. (MET), reported an acquisition of 916 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After this transaction, the filing shows 102,067 shares beneficially owned directly by the reporting person.
The filing notes these shares were issued as part of MetLife's non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
MetLife director Carlos M. Gutierrez acquired 534 shares of MetLife, Inc. common stock on 10/01/2025 as part of the company’s non-management director compensation program that pays a portion of retainer fees in common stock. After the purchase, Mr. Gutierrez directly owns 24,385 shares and indirectly holds 18,807 shares through the Carlos M. Gutierrez Trust. The transaction was reported on a Form 4 filed and signed via attorney-in-fact on 10/03/2025.
MetLife director William E. Kennard reported an acquisition of 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction, the reporting person beneficially owned 44,452 shares. The filing notes these shares were part of non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Some shares are held indirectly through the MetLife Policyholder Trust, which holds shares allocated to eligible policyholders of a MetLife subsidiary.
Johnson Jeh C., a non-management director of MetLife, Inc. (MET), reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction the reporting person beneficially owns 7,372 shares. The shares were paid as part of non-management director retainer fees and the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Denise M. Morrison, identified as a director of MetLife, Inc. (MET), reported a non-derivative acquisition of 534 shares of MetLife common stock on 10/01/2025. The shares were issued as part of MetLife's non-management director compensation and recorded with a price of $0 (retainer paid in stock). Following the transaction the reporting person beneficially owned 33,351 shares. The Form 4 filing was signed on 10/03/2025 by an attorney-in-fact. The disclosure states these shares represent a portion of the director retainer paid in company stock.
Form 144 notice for MetLife, Inc. (MET) reports a proposed sale of 333 shares of common stock, with an aggregate market value of $27,429.21, intended for sale on 10/01/2025 on the NYSE. The filing lists the securities' original acquisition dates: 114 shares purchased 06/20/2014 and 219 shares purchased 12/19/2014, both bought from GOLDMAN SACHS and paid in cash. The filing also discloses multiple sales of MetLife common stock by MetLife-related accounts during the past three months, including transactions on 07/28/2025, 07/31/2025 and 09/19/2025 with amounts and gross proceeds specified. Certain filer contact and CIK fields appear blank in the provided content.
MetLife, Inc. disclosed preliminary, unaudited estimates that its variable investment income for the quarter ended September 30, 2025 is expected to meet the company’s quarterly target of $425 million (pre-tax). This target is presented in the context of full-year 2025 guidance of approximately $1.7 billion (pre-tax) for variable investment income, which includes returns from private equity, real estate and other funds and prepayment fees. The company notes these figures are estimated and prepared in good faith on a basis consistent with prior periods but financial closing procedures are not complete and actual results could be materially different. These preliminary results are not substitutes for audited GAAP financial statements and are not necessarily indicative of future periods.